- ANGLE's Parsortix system was widely showcased by the company's customers and key opinion leaders in the field of circulating tumour cells in presentations at Europe's leading CTC conference, the Third International Advances in Circulating Tumour Cells (ACTC) Symposium, which took place in Rhodes, Greece, on 4-7 Oct.

Professor Stuart Martin from the University of Maryland School of Medicine, USA, presented new breakthrough research using ANGLE's Parsortix system at the conference.

During his plenary session, Martin presented results from a proof of principle study for a real-time analytical protocol to assess drug response on live CTCs harvested from a simple blood test using Parsortix.

Martin said: 'The unique ability of Parsortix to rapidly capture live CTCs and CTC clusters from patient blood samples preserving their metastatic CTC behaviours gives us a platform for testing new drugs that could reduce cancer metastasis in patients.

'Recovering living CTCs for immediate imaging within the Parsortix cassette really advances our goals of testing drug responses in patient CTCs, while allowing us to avoid the problems with growing CTCs in the laboratory.' ANGLE founder and chief executive, Andrew Newland said: 'The significant number of presentations featuring Parsortix at this leading conference for advances in the field of circulating tumour cells suggests that ANGLE's strategy of promoting research use sales to drive widespread adoption of its CTC harvesting system is working well.

'Parsortix is compatible with numerous downstream analysis systems and our aim is for it to become the default system for cancer liquid biopsy, a growing market that is expected to reach $14 billion in the United States alone by 2025.'

Separately, ANGLE announced that one of its customers had successfully grown circulating tumour cells (CTCs) harvested by Parsortix in the laboratory.

It said this was the first time the ability to culture CTCs harvested from blood using Parsortix had been published.

The CTCs were isolated from diagnostic leukapheresis (DLA) blood product.

At 8:12am: [LON:AGL] Angle PLC share price was +1.5p at 39.75p

Story provided by